Tabrizi Sepehr N, Law Irwin, Buadromo Eka, Stevens Matthew P, Fong James, Samuela Josaia, Patel Mahomed, Mulholland E Kim, Russell Fiona M, Garland Suzanne M
Regional WHO HPV Reference Laboratory, Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Parkville, Vic. 3052, Australia.
Sex Health. 2011 Sep;8(3):338-42. doi: 10.1071/SH10083.
There is currently limited information about human papillomavirus (HPV) genotype distribution in women in the South Pacific region. This study's objective was to determine HPV genotypes present in cervical cancer (CC) and precancers (cervical intraepithelial lesion (CIN) 3) in Fiji.
Cross-sectional analysis evaluated archival CC and CIN3 biopsy samples from 296 women of Melanesian Fijian ethnicity (n=182, 61.5%) and Indo-Fijian ethnicity (n=114, 38.5%). HPV genotypes were evaluated using the INNO-LiPA assay in archival samples from CC (n=174) and CIN3 (n=122) among women in Fiji over a 5-year period from 2003 to 2007.
Overall, 99% of the specimens tested were HPV DNA-positive for high-risk genotypes, with detection rates of 100%, 97.4% and 100% in CIN3, squamous cell carcinoma (SCC) and adenosquamous carcinoma biopsies, respectively. Genotypes 16 and 18 were the most common (77%), followed by HPV 31 (4.3%). Genotype HPV 16 was the most common identified (59%) in CIN3 specimens, followed by HPV 31 (9%) and HPV 52 (6.6%). Multiple genotypes were detected in 12.5-33.3% of specimens, depending on the pathology.
These results indicated that the two most prevalent CC-associated HPV genotypes in Fiji parallel those described in other regions worldwide, with genotype variations thereafter. These data suggest that the currently available bivalent and quadrivalent HPV vaccines could potentially reduce cervical cancers in Fiji by over 80% and reduce precancers by at least 60%.
目前关于南太平洋地区女性人乳头瘤病毒（HPV）基因型分布的信息有限。本研究的目的是确定斐济宫颈癌（CC）和癌前病变（宫颈上皮内瘤变（CIN）3级）中存在的HPV基因型。
横断面分析评估了296名美拉尼西亚斐济族（n = 182，61.5%）和印度斐济族（n = 114，38.5%）女性的存档CC和CIN3活检样本。在2003年至2007年的5年期间，使用INNO-LiPA检测法对斐济女性中CC（n = 174）和CIN3（n = 122）的存档样本中的HPV基因型进行评估。
总体而言，99%的检测标本高危基因型HPV DNA呈阳性，CIN3、鳞状细胞癌（SCC）和腺鳞癌活检中的检出率分别为100%、97.4%和100%。16型和18型是最常见的基因型（77%），其次是HPV 31型（4.3%）。HPV 16型是CIN3标本中最常见的基因型（59%），其次是HPV 31型（9%）和HPV 52型（6.6%）。根据病理情况，12.5% - 33.3%的标本中检测到多种基因型。
这些结果表明，斐济与CC相关的两种最常见HPV基因型与世界其他地区描述的一致，之后存在基因型差异。这些数据表明，目前可用的二价和四价HPV疫苗可能使斐济的宫颈癌减少80%以上，癌前病变减少至少60%。
